Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A site-wide announcement says NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence.” The study page still displays a 403 error.
    Difference
    1%
    Check dated 2026-10-22T14:28:35.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer now displays site revision v3.7.2 instead of v3.7.1. The page continues to show a 403 Forbidden error rather than the study record.
    Difference
    0.2%
    Check dated 2026-10-15T13:29:58.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The error page’s footer revision label changed from v3.7.0 to v3.7.1; the study information remains unavailable.
    Difference
    0.2%
    Check dated 2026-10-08T14:28:03.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error page instead of the study record content. This indicates that access to the record is blocked, rather than representing a substantive update to the study details.
    Difference
    18%
    Check dated 2026-09-24T18:40:14.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The page shows a new revision version (v3.7.0) replacing the previous v3.6.6, indicating an update to the page’s revision metadata. This appears to be a general update rather than a substantive change to the study content or eligibility details.
    Difference
    0.0%
    Check dated 2026-09-17T22:45:47.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The study's locations list was updated to reflect fewer active sites: the page now shows 39 locations, and several previously listed sites (e.g., Busan, Michalovce, Cebu, San Luis Potosí City, Mexico City, and other Mexican sites) were removed.
    Difference
    0.6%
    Check dated 2026-09-03T22:18:42.000Z thumbnail image

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.